Cagla Rencuzogullari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cagla Rencuzogullari has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Adem Alemdar
Department of Medical Biology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan, 24100, Turkiye
1 shared publication - Adem Deligönül
Bursa Uludağ University, Faculty of Medicine, Department of Medical Oncology, Bursa, Türkiye
1 shared publication - Atil Bisgin
Cukurova University Medical Faculty, Department of Medical Genetics & Cukurova University AGENTEM (Adana Genetic Diseases Diagnosis and Treatment Center), Adana, Turkey
1 shared publication - Bedia Cakmakoglu
Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul 34093, Türkiye
1 shared publication - Berkcan Dogan
Department of Medical Genetics, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Turkey
1 shared publication - Bilge Dundar
Department of Laboratory Medicine and Pathology Mayo Clinic Rochester MN USA
1 shared publication
Latest Publications
- 3 July 2023
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 19 (3) , 235-252
A Multicenter Study of Genotype Variation/Demographic Patterns in 2475 Individuals Including 1444 Cases With Breast Cancer in Turkey
Breast cancer (BC) is the most common cancer type in women and may be inherited, mostly in an autosomal dominant pattern. The clinical diagnosis of BC relies on the published diagnostic criteria, and analysis of two genes, BRCA1 and BRCA2, which are strongly associated with BC, are included in these criteria. The aim of this study was to compare BC index cases with non-BC individuals in terms of genotype and diagnostic features to investigate the genotype/demographic information association. Mutational analyses for the BRCA1/BRCA2 genes was performed in 2475 individuals between 2013-2022 from collaborative centers across Turkey, of whom 1444 with BC were designated as index cases. Overall, mutations were identified in 17% (421/2475), while the percentage of mutation carriers in cases of BC was similar, 16.6% (239/1444). BRCA1/BRCA2 gene mutations were detected in 17.8% (131/737) of familial cases and 12% (78/549) of sporadic cases. Mutations in BRCA1 were found in 4.9%, whereas 12% were in BRCA2 (p<0.05). Meta-analyses were performed to compare these results with other studies of Mediterranean-region populations. Patients with BRCA2 mutations were significantly more common than those with BRCA1 mutations. In sporadic cases, there was a lower proportion with BRCA1/BRCA2 variants, as expected, and these results were consistent with the data of Mediterranean-region populations. However, the present study, because of the large sample size, revealed more robust findings than previous studies. These findings may be helpful in facilitating the clinical management of BC for both familial and non-familial cases.
- 3 July 2023
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 19 (3) , 235-252
A Multicenter Study of Genotype Variation/Demographic Patterns in 2475 Individuals Including 1444 Cases With Breast Cancer in Turkey
Breast cancer (BC) is the most common cancer type in women and may be inherited, mostly in an autosomal dominant pattern. The clinical diagnosis of BC relies on the published diagnostic criteria, and analysis of two genes, BRCA1 and BRCA2, which are strongly associated with BC, are included in these criteria. The aim of this study was to compare BC index cases with non-BC individuals in terms of genotype and diagnostic features to investigate the genotype/demographic information association. Mutational analyses for the BRCA1/BRCA2 genes was performed in 2475 individuals between 2013-2022 from collaborative centers across Turkey, of whom 1444 with BC were designated as index cases. Overall, mutations were identified in 17% (421/2475), while the percentage of mutation carriers in cases of BC was similar, 16.6% (239/1444). BRCA1/BRCA2 gene mutations were detected in 17.8% (131/737) of familial cases and 12% (78/549) of sporadic cases. Mutations in BRCA1 were found in 4.9%, whereas 12% were in BRCA2 (p<0.05). Meta-analyses were performed to compare these results with other studies of Mediterranean-region populations. Patients with BRCA2 mutations were significantly more common than those with BRCA1 mutations. In sporadic cases, there was a lower proportion with BRCA1/BRCA2 variants, as expected, and these results were consistent with the data of Mediterranean-region populations. However, the present study, because of the large sample size, revealed more robust findings than previous studies. These findings may be helpful in facilitating the clinical management of BC for both familial and non-familial cases.
- 30 September 2019
- Published by Marmara University in Clinical and Experimental Health Sciences
- Vol. 9 (3) , 228-231
Investigation of Potential Anticarcinogenic Effects of Corilagin in Lung Cancer Cells
- 30 September 2019
- Published by Marmara University in Clinical and Experimental Health Sciences
- Vol. 9 (3) , 228-231
Investigation of Potential Anticarcinogenic Effects of Corilagin in Lung Cancer Cells